8-K: Salarius Pharmaceuticals Implements 1-for-8 Reverse Stock Split to Regain Nasdaq Compliance

Salarius Pharmaceuticals has executed a 1-for-8 reverse stock split to meet Nasdaq's minimum bid price requirement, effective June 14, 2024.

Summary

• Salarius Pharmaceuticals has completed a 1-for-8 reverse stock split of its common stock.
• The reverse split was effective at 5:00 p.m. Eastern Time on June 14, 2024.
• Trading on a split-adjusted basis began on June 17, 2024, under a new CUSIP number 79400X404.
• The number of outstanding shares decreased from approximately 4.7 million to approximately 0.6 million.
• Stockholders who would have received fractional shares will receive cash based on the closing price on June 14, 2024.
• The reverse split does not change the number of authorized shares or the par value of the stock.
• Outstanding options and warrants, as well as shares reserved for future issuance under equity plans, have been adjusted accordingly.

Sentiment

Score: 5

Explanation: The document is neutral, detailing a necessary but potentially concerning action (reverse stock split) to maintain Nasdaq listing. It is not inherently positive or negative, but rather a procedural step.

Positives

• The reverse stock split is intended to help the company regain compliance with Nasdaq's minimum bid price requirement.
• The reverse split will not affect any stockholder's ownership percentage, except for cash payments for fractional shares.
• All outstanding options, warrants, and shares reserved for future issuance have been adjusted appropriately.

Negatives

• The reverse stock split was necessary to avoid potential delisting from the Nasdaq Capital Market.
• The reverse split reduces the number of outstanding shares, which may be perceived negatively by some investors.

Risks

• The company's ability to maintain compliance with Nasdaq listing requirements is not guaranteed.
• General market conditions and other risks detailed in the company's SEC filings could impact future performance.
• The reverse stock split may not be sufficient to maintain the share price above the minimum bid price.

Future Outlook

The company intends to maintain its Nasdaq listing and continue developing its cancer therapies. The company undertakes no obligation to publicly update any forward-looking statements.

Management Comments

• The reverse stock split is intended to enable Salarius to regain compliance with the $1.00 minimum closing bid price required for continued listing on the Nasdaq Capital Market.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low share prices. This action is often a sign of financial distress or a need to improve the company's image to attract investors.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism used by companies to regain compliance with exchange listing requirements, particularly the minimum bid price rule.
• Other companies in the biotech sector, such as Agenus Inc. and VBI Vaccines Inc., have also recently implemented reverse stock splits to maintain their Nasdaq listings.
• The 1-for-8 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-20 or more.
• The success of a reverse stock split in maintaining listing compliance depends on the company's ability to improve its financial performance and investor confidence.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, but their ownership percentage will remain the same, except for cash payments for fractional shares.
• Employees with stock options or shares under the company's equity plans will have their holdings adjusted accordingly.
• The company's ability to maintain its Nasdaq listing is important for investor confidence and the company's long-term viability.

Next Steps

• The company will continue to trade on the Nasdaq Capital Market under the new CUSIP number 79400X404.
• Stockholders with physical certificates will receive instructions from Equiniti Trust Company, LLC on how to exchange their certificates for post-split shares.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, common stock, share consolidation, stock split, Salarius Pharmaceuticals, SLRX